FluMist Rejuvenated With CDC Advisory Panel Endorsement; Effectiveness Data Still To Come
Executive Summary
US panel votes 12 to 2 to recommend use of nasal vaccine, which has been reformulated to include a new influenza A strain.
You may also be interested in...
AstraZeneca FluMist Supply Jumps With CDC's Seal Of Approval
US FDA's approval kept very limited amounts available the past two flu seasons; 2.7 million doses to be shipped for the 2018-2019 season.
Eggs May Be Culprit In Poor Flu Vaccine Performance This Year
US health authorities, manufacturers investigating why egg-based product appears to have lower effect in adults compared to cell-based flu vaccine.
FluMist May Not Get CDC Seal Of Approval For Several Years
CDC advisory committee wants vaccine effectiveness data for H1N1 component but that is not the predominant strain this season; AstraZeneca is not giving up.